Carisma Therapeutics Inc
CARM
Market Cap$39.26M
Close$
$-0.29
172.5% downside
Current Fair Value
172.5% downsideOvervalued by 172.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $39.26 Million |
|---|---|
| Enterprise Value | $42.65 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.59 |
| Beta | 0 |
| Outstanding Shares | 41,543,553 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.54 |
|---|---|
| PEG | 1.06 |
| Price to Sales | - |
| Price to Book Ratio | -0.4 |
| Enterprise Value to Revenue | 2.63 |
| Enterprise Value to EBIT | -1.02 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | -0.3 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Carisma Therapeutics Inc
35 employees
CEO: Thomas Cannell Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage ...